 ContraFect Corporation CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the appointment of Lishan Aklog, M.D. to the Companys board of directors Board. Dr. Aklog is Co-Founder, Chairman and Chief Executive Officer of PAVmed Inc. PAVM. Dr. Aklog has a long history of successful leadership and innovation in the healthcare industry, in addition to his expertise in cardiovascular disease and complications, said Roger J. Pomerantz, M.D., President, Chief Executive Officer, and Chairman of ContraFect. 